Development of an anti-guinea pig CD4 monoclonal antibody for depletion of CD4+ T cells in vivo

Brianne N. Banasik, Clarice L. Perry, Celeste A. Keith, Nigel Bourne, Hubert Schäfer, Gregg Milligan

Research output: Contribution to journalArticle

Abstract

The guinea pig serves as a useful animal model for a number of human diseases and has played an important role during development and testing of experimental vaccines and disease therapies. However, the availability of reagents to examine the immunological response in this species is very limited. Monoclonal antibodies (mAb) specific for cell surface proteins or products of immune cells have been useful tools for characterizing and quantifying immune responses in humans and in murine models of human disease, but very few similar reagents are available for characterizing and manipulating the immune response of guinea pigs. A rat IgG2a mAb specific for guinea pig CD4 has previously been described and was shown to inhibit T cell proliferation, but was inefficient at depleting CD4+ T cells in vivo. We hypothesized that the in vivo CD4+ T cell depletion function of this mAb could be improved by expression of the rat IgG2b heavy chain. We show that the purified mAb from an IgG2b class-switch variant, but not the parental IgG2a mAb, significantly depleted CD4+ T cells from secondary lymphoid tissue of guinea pigs. Further, treatment of guinea pigs with the IgG2b mAb at 2.0 mg/kg resulted in depletion of CD4+ T cells from peripheral blood and spleen. The use of this modified antibody to specifically alter the immune response of guinea pigs should prove useful in a number of guinea pig infectious disease models.

Original languageEnglish (US)
Article number112654
JournalJournal of Immunological Methods
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Guinea Pigs
Monoclonal Antibodies
T-Lymphocytes
Active Immunotherapy
Investigational Therapies
Immunoglobulin Isotypes
Lymphoid Tissue
Communicable Diseases
Membrane Proteins
Spleen
Animal Models
Cell Proliferation
Antibodies

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Development of an anti-guinea pig CD4 monoclonal antibody for depletion of CD4+ T cells in vivo. / Banasik, Brianne N.; Perry, Clarice L.; Keith, Celeste A.; Bourne, Nigel; Schäfer, Hubert; Milligan, Gregg.

In: Journal of Immunological Methods, 01.01.2019.

Research output: Contribution to journalArticle

@article{f2a23bfbbc5b43e490d55fd4bc7f4ee8,
title = "Development of an anti-guinea pig CD4 monoclonal antibody for depletion of CD4+ T cells in vivo",
abstract = "The guinea pig serves as a useful animal model for a number of human diseases and has played an important role during development and testing of experimental vaccines and disease therapies. However, the availability of reagents to examine the immunological response in this species is very limited. Monoclonal antibodies (mAb) specific for cell surface proteins or products of immune cells have been useful tools for characterizing and quantifying immune responses in humans and in murine models of human disease, but very few similar reagents are available for characterizing and manipulating the immune response of guinea pigs. A rat IgG2a mAb specific for guinea pig CD4 has previously been described and was shown to inhibit T cell proliferation, but was inefficient at depleting CD4+ T cells in vivo. We hypothesized that the in vivo CD4+ T cell depletion function of this mAb could be improved by expression of the rat IgG2b heavy chain. We show that the purified mAb from an IgG2b class-switch variant, but not the parental IgG2a mAb, significantly depleted CD4+ T cells from secondary lymphoid tissue of guinea pigs. Further, treatment of guinea pigs with the IgG2b mAb at 2.0 mg/kg resulted in depletion of CD4+ T cells from peripheral blood and spleen. The use of this modified antibody to specifically alter the immune response of guinea pigs should prove useful in a number of guinea pig infectious disease models.",
author = "Banasik, {Brianne N.} and Perry, {Clarice L.} and Keith, {Celeste A.} and Nigel Bourne and Hubert Sch{\"a}fer and Gregg Milligan",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.jim.2019.112654",
language = "English (US)",
journal = "Journal of Immunological Methods",
issn = "0022-1759",
publisher = "Elsevier",

}

TY - JOUR

T1 - Development of an anti-guinea pig CD4 monoclonal antibody for depletion of CD4+ T cells in vivo

AU - Banasik, Brianne N.

AU - Perry, Clarice L.

AU - Keith, Celeste A.

AU - Bourne, Nigel

AU - Schäfer, Hubert

AU - Milligan, Gregg

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The guinea pig serves as a useful animal model for a number of human diseases and has played an important role during development and testing of experimental vaccines and disease therapies. However, the availability of reagents to examine the immunological response in this species is very limited. Monoclonal antibodies (mAb) specific for cell surface proteins or products of immune cells have been useful tools for characterizing and quantifying immune responses in humans and in murine models of human disease, but very few similar reagents are available for characterizing and manipulating the immune response of guinea pigs. A rat IgG2a mAb specific for guinea pig CD4 has previously been described and was shown to inhibit T cell proliferation, but was inefficient at depleting CD4+ T cells in vivo. We hypothesized that the in vivo CD4+ T cell depletion function of this mAb could be improved by expression of the rat IgG2b heavy chain. We show that the purified mAb from an IgG2b class-switch variant, but not the parental IgG2a mAb, significantly depleted CD4+ T cells from secondary lymphoid tissue of guinea pigs. Further, treatment of guinea pigs with the IgG2b mAb at 2.0 mg/kg resulted in depletion of CD4+ T cells from peripheral blood and spleen. The use of this modified antibody to specifically alter the immune response of guinea pigs should prove useful in a number of guinea pig infectious disease models.

AB - The guinea pig serves as a useful animal model for a number of human diseases and has played an important role during development and testing of experimental vaccines and disease therapies. However, the availability of reagents to examine the immunological response in this species is very limited. Monoclonal antibodies (mAb) specific for cell surface proteins or products of immune cells have been useful tools for characterizing and quantifying immune responses in humans and in murine models of human disease, but very few similar reagents are available for characterizing and manipulating the immune response of guinea pigs. A rat IgG2a mAb specific for guinea pig CD4 has previously been described and was shown to inhibit T cell proliferation, but was inefficient at depleting CD4+ T cells in vivo. We hypothesized that the in vivo CD4+ T cell depletion function of this mAb could be improved by expression of the rat IgG2b heavy chain. We show that the purified mAb from an IgG2b class-switch variant, but not the parental IgG2a mAb, significantly depleted CD4+ T cells from secondary lymphoid tissue of guinea pigs. Further, treatment of guinea pigs with the IgG2b mAb at 2.0 mg/kg resulted in depletion of CD4+ T cells from peripheral blood and spleen. The use of this modified antibody to specifically alter the immune response of guinea pigs should prove useful in a number of guinea pig infectious disease models.

UR - http://www.scopus.com/inward/record.url?scp=85070912673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070912673&partnerID=8YFLogxK

U2 - 10.1016/j.jim.2019.112654

DO - 10.1016/j.jim.2019.112654

M3 - Article

JO - Journal of Immunological Methods

JF - Journal of Immunological Methods

SN - 0022-1759

M1 - 112654

ER -